This dataset contains summary data visualizations and clinical data from a broad sampling of 255 sarcomas from 255 patients. The data was gathered as part of the PanCancer Atlas initiative, which aims to answer big, overarching questions about cancer by examining the full set of tumors characterized in the robust TCGA dataset. The clinical data includes mutation count, information about mutated genes,...

This dataset contains summary data visualizations and clinical data from the targeted sequencing of 10,000 clinical cases using the MSK-IMPACT assay. The clinical data includes mutation count, information about mutated genes, tumor mutational burden calculations, tissue site from which the sample was derived, tumor purity among other relevant data points. The data set also includes copy-number segment...

TCGA Sarcoma. Source data from GDAC Firehose. Previously known as TCGA Provisional. This dataset contains summary data visualizations and clinical data from a broad sampling of 200 carcinomas from 200 patients. The data was gathered as part of the Broad Institute of MIT and Harvard Firehose initiative, a cancer analysis pipeline. The clinical data includes mutation count, information about mutated...

This dataset contains the summary data visualizations and clinical data from Whole-exome sequencing of 206 Adult Soft Tissue Sarcoma tumor/normal pairs. from 206 patients. Clinical data includes: Cancer Type, Mutation Count, Fraction Genome Altered, Demographic Information, Adjuvant Postoperative Pharmaceutical Therapy Administered Indicator, AMP 12q15 CDK4, AMP 12q15 DDIT3, AMP 12q15 FRS2, AMP 12q15...

Summary from GEO: "Current research on CDK4/6 inhibitors (CDK4/6i) in the pre-clinical and clinical spaces are largely concerned with gaining a deeper understanding of how these drugs delay tumor growth, and how to prevent cancer cell resistance. By coordinating a first-in-kind phase II clinical trial of the CDK4/6i abemaciclib for patients with progressive dedifferentiated liposarcoma (DDLS) with...

Summary from GEO: "We validated patient's tumor-derived cell lines of liposarcoma by analysing copy number alterations using aCGH or WGS and comparing with the original tumor tissues." Overall design from GEO: "Examination of copy number alterations for 2 cell lines, one of the original tumor, one PDX-tumor and its original tumor."

Summary from GEO: "We validated patient's tumor-derived cell lines of liposarcoma by analysing copy number alterations using aCGH or WGS and comparing with the original tumor tissues." Overall design from GEO: "Examination of copy number alterations for 2 cell lines, one of the original tumor, one PDX-tumor and its original tumor."